| Drug General Information |
| Drug ID |
D0YB9P
|
| Former ID |
DNC004364
|
| Drug Name |
GLUTAMATE
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C5H9NO4
|
| Canonical SMILES |
C(CC(=O)O)C(C(=O)O)N
|
| InChI |
1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1
|
| InChIKey |
WHUUTDBJXJRKMK-GSVOUGTGSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Metabotropic glutamate receptor 2 |
Target Info |
Inhibitor |
[2]
|
|---|
| Metabotropic glutamate receptor 8 |
Target Info |
Inhibitor |
[1]
|
| Metabotropicglutamate receptor 1 |
Target Info |
Inhibitor |
[2]
|
| Glutamate receptor, ionotropic kainate 1 |
Target Info |
Inhibitor |
[3]
|
| NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[4]
|
| Metabotropic glutamate receptor 5 |
Target Info |
Inhibitor |
[2]
|
| Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Inhibitor |
[4]
|
| Adenosine A3 receptor |
Target Info |
Inhibitor |
[5]
|
| Glutamate receptor 1 |
Target Info |
Inhibitor |
[6]
|
| Glutamate [NMDA] receptor subunit epsilon 1 |
Target Info |
Inhibitor |
[4]
|
| Glutamate receptor AMPA subtype |
Target Info |
Inhibitor |
[3]
|
| Metabotropic glutamate receptor 4 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Glutamatergic synapse
|
|
Cocaine addictionhsa04080:Neuroactive ligand-receptor interaction
|
|
Glutamatergic synapsehsa04020:Calcium signaling pathway
|
|
FoxO signaling pathway
|
|
Gap junction
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Long-term depression
|
|
Estrogen signaling pathwayhsa04080:Neuroactive ligand-receptor interaction
|
|
Glutamatergic synapsehsa04014:Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Circadian entrainment
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Huntington's diseasehsa04014:Ras signaling pathway
|
|
Dopaminergic synapse
|
|
Alcoholism
|
|
Systemic lupus erythematosushsa04024:cAMP signaling pathway
|
|
Nicotine addictionhsa04014:Ras signaling pathway
|
|
Systemic lupus erythematosushsa04080:Neuroactive ligand-receptor interaction
|
|
Taste transduction
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group II pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathwayP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Endogenous cannabinoid signalingP00029:Huntington disease
|
|
Metabotropic glutamate receptor group I pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00037:Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
Reelin signaling pathwayephbfwdpathway:EPHB forward signalingreelinpathway:Reelin signaling pathway
|
|
Reactome
|
G alpha (i) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-418594:G alpha (i) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-416476:G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-3928662:EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascadeR-HSA-416476:G alpha (q) signalling events
|
|
RAF/MAP kinase cascadeR-HSA-417973:Adenosine P1 receptors
|
|
G alpha (i) signalling eventsR-HSA-204005:COPII (Coat Protein 2) Mediated Vesicle Transport
|
|
Trafficking of AMPA receptors
|
|
Trafficking of GluR2-containing AMPA receptors
|
|
Cargo concentration in the ERR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
|
|
RAF/MAP kinase cascadeR-HSA-418594:G alpha (i) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)
|
|
WikiPathways
|
GPCRs, Class C Metabotropic glutamate, pheromone
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP501:GPCRs, Class C Metabotropic glutamate, pheromone
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, OtherWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic CellWP706:SIDS Susceptibility Pathways
|
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Spinal Cord Injury
|
|
BDNF signaling pathway
|
|
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
BDNF signaling pathwayWP80:Nucleotide GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
|
|
Alzheimers DiseaseWP501:GPCRs, Class C Metabotropic glutamate, pheromone
|
| References |
| REF 1 | Bioorg Med Chem. 2007 May 1;15(9):3161-70. Epub 2007 Feb 22.Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first class of 3'-substituted trans C1'-2'-2-(2'-phosphonocyclopropyl)glycines. |
|---|
| REF 2 | J Med Chem. 2007 Sep 20;50(19):4630-41. Epub 2007 Aug 29.Synthesis, molecular modeling studies, and preliminary pharmacological characterization of all possible 2-(2'-sulfonocyclopropyl)glycine stereoisomers as conformationally constrained L-homocysteic acid analogs. |
|---|
| REF 3 | J Med Chem. 2010 May 27;53(10):4110-8.4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues. |
|---|
| REF 4 | J Med Chem. 1992 Dec 11;35(25):4720-6.Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. |
|---|
| REF 5 | J Med Chem. 2005 Nov 3;48(22):6887-96.2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. |
|---|
| REF 6 | J Med Chem. 2008 Oct 23;51(20):6614-8. Epub 2008 Sep 24.1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators. |
|---|
